View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
March 5, 2021

SIRION and Sanofi partner on next-gen AAV gene therapy vectors

SIRION and Sanofi are partnering to develop improved AAV vectors to overcome some of the challenges facing gene therapies. The partners will do this by combining their proprietary platforms and working closely with AAV pioneer Professor Dirk Grimm from Heidelberg University Hospital in Germany.

By Allie Nawrat

Germany-based SIRION Biotech has signed a gene therapy collaboration with French pharma giant Sanofi. The pair will work with Heidelberg University Hospital’s Professor Dirk Grimm in Germany to develop next-generation tissue-selective adeno-associated virus (AAV) vectors for gene therapies.

To do this, Sanofi and SIRION will leverage both of their gene therapy technology platforms, as well as Grimm’s AAV biology expertise, to develop AAV capsids with a good safety profile, which also allow for more specific and higher efficiency of gene delivery. The resulting gene therapies are aiming to be efficient, low-dose and scalable, which will help to bring gene therapies to new patients.

Sanofi global head of genomic medicine Dr Christian Mueller said: “This partnership adds to our expanding toolbox of technologies in the important, emerging area of gene therapeutics.

“Leveraging our expertise in virus-based vaccine and viral vector manufacturing together with Professor Grimm’s cutting-edge AAV capsid evolution technology and SIRION’s expertise and capabilities in AAV vector manufacturing will allow us to better address unmet medical needs and open new frontiers for drug discovery in genomic medicine.”

The financial terms of the deal have not been disclosed by either party.

SIRION’s viral vector technologies

SIRION’s work centres around its goal of “sparking a new generation of viral vector technologies for cell and gene therapy, and vaccination development,” explains the company’s founder and CEO Dr. Christian Thirion. “This meant building novel, all-encompassing viral vector platforms for AAV, lentivirus, and adenovirus, to expedite its partners’ advances in the drug, cosmetics and food industries.”

As part of SIRION’s work in viral vectors, the company works closely with Professor Grimm to create “novel AAV capsids with enhanced tissue targeting,” adds Thirion. With its viral vector platforms, SIRION aims to overcome some of the challenges facing existing gene therapies.

“Despite the huge potential and clinical benefits of gene therapy, challenges clearly remain regarding immunogenicity, duration of treatment, specificity of gene transfer, and viral load requirements,” Thirion says. “However, the benefits of the therapy outweigh the potential risks, and offer new treatment options and real hope for patients.” To reduce dosage requirements, there is a need for “more targeted expression of the therapeutic gene and higher expression levels”.

Being able to design AAV vectors with improved efficacy can allow gene therapies to enter clinical trials at efficient, low doses, with the aim of expanding their impact.

Sanofi as the perfect partner

“Sanofi is an ideal partner with decades-long experience in treating a multitude of disorders and exploring viral vectors as a therapeutic modality,” adds Thirion. For instance, Genzyme, one of the front-runners in AAV technology in the field of gene therapy, is part of the Sanofi group.

Thirion concludes: “We believe that through this partnership with Sanofi within these large disease fields, AAV-based gene therapies will provide novel treatment options to many millions of patients worldwide suffering from disorders affecting major human organs.”

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology